3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
23
Recurrence
3
Neoplasms, Plasma Cell
2
Lymphoma
2
beta-Thalassemia
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmablastic Lymphoma
1
Neoplasms
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphadenopathy
1
Leukemia, Myeloid, Acute
1
HIV Infections
1
Anemia, Sickle Cell
1
Interventions
Etoposide
3
daratumumab
2
Vincristine
2
Prednisone
2
Doxorubicin
2
Cyclophosphamide
2
prednylidene
1
pomalidomide
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Dexamethasone
1
Cytarabine
1
Carmustine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmablastic Lymphoma
×
Bortezomib
×
30 days
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled